Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis by Arias, JL et al.
Journal of Controlled Release 197 (2015) 190–198
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre lNanobody conjugated PLGA nanoparticles for active targeting of
African TrypanosomiasisJosé L. Arias a, Juan D. Unciti-Broceta b,c,d, José Maceira b,c,d, Teresa del Castillo b,c,d, José Hernández-Quero b,
Stefan Magez e,f, Miguel Soriano d,g,1, José A. García-Salcedo b,c,d,⁎,1
a Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Granada, Granada, Spain
b Unidad de Enfermedades Infecciosas y Microbiología, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
c Instituto de Parasitología y Biomedicina “López-Neyra” (IPBLN-CSIC), PTS Granada, Armilla, Spain
d GENYO, Centro de Genómica e Investigación Oncológica: Pﬁzer/Universidad de Granada/Junta de Andalucía, PTS Granada, Granada, Spain
e Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium
f Department of Structural Biology, VIB, Vrije Universiteit Brussel, Brussels, Belgium
g Departamento de Agronomía, Universidad de Almería, Almería, Spain⁎ Corresponding author at: GENYO, Centro de Genóm
Pﬁzer/Universidad de Granada/Junta de Andalucía, PTS G
114, 18016 Granada, Spain. Tel.: +34 968 71 55 00x165;
E-mail address: jags@genyo.es (J.A. García-Salcedo).
1 Both authors contributed equally.
http://dx.doi.org/10.1016/j.jconrel.2014.11.002
0168-3659/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 14 July 2014
Accepted 3 November 2014
Available online 10 November 2014
Keywords:
Polymeric nanoparticles
PLGA
Nanobody nanoparticles conjugation
PEGylation
Speciﬁc cell targeting
Human African trypanosomiasisTargeted delivery of therapeutics is an alternative approach for the selective treatment of infectious diseases. The
surface of African trypanosomes, the causative agents of African trypanosomiasis, is covered by a surface coat
consisting of a single variant surface glycoprotein, termed VSG. This coat is recycled by endocytosis at a very
high speed, making the trypanosome surface an excellent target for the delivery of trypanocidal drugs. Here,
we report the design of a drug nanocarrier based on poly ethylen glycol (PEG) covalently attached (PEGylated)
to poly(D,L-lactide-co-glycolide acid) (PLGA) to generate PEGylated PLGA nanoparticles. This nanocarrier was
coupled to a single domain heavy chain antibody fragment (nanobody) that speciﬁcally recognizes the surface
of the protozoan pathogen Trypanosoma brucei. Nanoparticles were loaded with pentamidine, the ﬁrst-line
drug for T. b. gambiense acute infection. An in vitro effectiveness assay showed a 7-fold decrease in the
half-inhibitory concentration (IC50) of the formulation relative to free drug. Furthermore, in vivo therapy
using a murine model of African trypanosomiasis demonstrated that the formulation cured all infected
mice at a 10-fold lower dose than the minimal full curative dose of free pentamidine and 60% of mice at a
100-fold lower dose. This nanocarrier has beendesignedwith components approved for use inhumans and loaded
with a drug that is currently in use to treat the disease. Moreover, this ﬂexible nanobody-based system can be
adapted to load any compound, opening a range of new potential therapies with application to other diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
African trypanosomiasis is a disease with a devastating socio-
economic impact in sub-SaharanAfrica. The causative agent, Trypanosoma
brucei ssp, is transmitted by the bite of and infected ﬂy of the genus
Glossina to humans or domestic livesock [1–3]. HumanAfrican trypanoso-
miasis (HAT), also known as sleeping sickness, is caused by T. b.
gambiense or T. b. rhodesiense and is typically fatalwithout chemotherapy.
HAT is endemic in 36 African countries and around 60million people are
at risk of being infected. The prevalence has been variable during the
twentieth century coinciding the re-emergence of the number of cases
with periods of famine and war [4,5]. The public health situation has im-
proved recently with surveillance and control efforts averting more thanica e Investigación Oncológica:
ranada Avda. de la Ilustración
fax: +34 958 63 70 71.1.6 millions disability-adjusted life years in 2004. However, displacement
of populations, conﬂicts, and povertymay lead to increased transmission,
with severe social and economic consequences.
African trypanosomes are extracellular parasites transmitted by the
bite of tsetse ﬂies. Trypanosomes are able to evade the host immune
systemby changing theVariant SurfaceGlycoprotein (VSG), in a process
termed antigenic variation [6,7]. TheVSG is organized as densely packed
dimers and works as a physical barrier impeding antibody recognition
of invariant inner epitopes (Fig. 1). The rate of parasite surface turnover
is very high and occurs in the ﬂagellar pocket, which is an invagination
of the plasma membrane around the base of the ﬂagellum and the sole
site for endocytosis [8]. This is a defence mechanism to degrade host
antibodies bound to the surface of the parasite [9,10] but is also
important for the uptake of some essential nutrients from the host
blood, such as transferrin and lipoproteins [11,12].
Antigenic variation eliminates the possibility of developing an
effective vaccine, leaving chemotherapy as the only method to ﬁght
against HAT disease. However, the drugs currently in use to treat
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Fig. 1.A) Illustration of the trypanosome surface. NbAn33 recognizes a hidden epitopewithin the glycophosphatidylinositol (GPI) anchor of the variant surface glycoprotein. B) Illustration
of a NbAn33-pentamidine-PLGA NP.
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Fig. 2. Schemeof a conventional IgG antibody. (A), a camelid heavy-chain IgG antibody (B)
and the variable domain of heavy chain antibodies, VHH, also known as a nanobody (C).
Conventional antibodies have two identical heavy chains, formed by VH, CH1, CH2 and
CH3 domains and two identical light chains, VL and CL domains. Heavy-chain antibodies
contain a single VHH and two constant domains (CH2 and CH3). A Nanobody is the VHH
domain of heavy-chain antibodies obtained by recombinant gene technology. CH1-3:
constant domains of heavy chain. CL: constant domain of light chain. VH: variable domain
of heavy chain. VL: variable domain of light chain.
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including encephalopathy, toxicity and death [13,14]. Currently,
there are only ﬁve licensed drugs for the treatment of HAT. Pentamidine
and suramin are suitable for treating the disease before parasites invade
the central nervous system; pentamidine is the drug of choice in the
treatment of ﬁrst-stage T. b. gambiense HAT, and suramin is used
for ﬁrst-stage T. b. rhodesiense HAT [13,14]. Melarsoprol, eﬂornithine
and eﬂornithine in combination with nifurtimox are the available
treatments for advanced disease. Clearly, alternative therapeutic
strategies are needed.
Nowadays, there are two approaches to develop new therapies: one
is the search for new drugs and the other is the optimisation of actual
formulations and their applications [15]. Design of nanoscale devices
for drug-delivery is one of the most important goals in medicine
and pharmaceutical technology [16]. Different systems based on nano-
particles (NPs) have been developed, including inorganic, magnetic
and polymeric NPs [17]. These systems have many advantages when
compared with conventional therapies. They protect drugs against
oxidoreduction and enzymatic reactions, increasing the bioavailability
and reducing the effective doses and negative side effects [17]. Incor-
poration of poly ethylene glycol (PEG) molecules on their surface
(PEGylation) increases nanoparticle circulation times by reducing
liver uptake. Nanoparticle PEGylation also provides moieties to attach
biofunctional molecules for speciﬁc cell or organ targeting, such as
antibodies [18,19].
Poly (lactic-co-glycolic acid) (PLGA) is a versatile polymer that is
widely used for drug encapsulation through the formulation of NPs.
PLGA is biodegradable and biocompatible and its use in humans for
parenteral administration has been approved by the Food and Drug
Administration and the European Medicine Agency [20]. The formu-
lations andmethods of PLGANPs synthesis arewell standardized and
the NPs are adaptable to different types of drugs and administration
routes. Moreover, their biological interaction with the environment
and the rate of drug release can be modulated by modifying their
physicochemical properties like shape, surface charge and hydro-
phobicity [21–23].
Nanobodies are single-domain antibody fragments derived from
functional heavy-chain antibodies (HCAbs) of camelids [24–27] (Fig. 2).
Unlike conventional antibodies, which are constituted of two identical
heavy-chains and two identical light-chains, heavy-chain antibodies
from camelids have lost the light-chains (Fig. 2). The heavy chain of
HCAbs is composed of three instead of four globular domains: two
constant domains (CH2-CH3) with high homology to conventional
antibodies and one variable domain [28,29]. The CH1 domain of
conventional antibodies is lost. The variable domain (nanobody),
can be cloned and expressed through recombinant gene technology,
and is fully functional [30].Nanobodies have several advantageous properties compared to
conventional antibodies: i) small size (15 kDa), which is suitable for
targeting epitopes in obstructed locations; ii) high afﬁnity and speciﬁcity;
iii) high stability and solubility; iv) not immunogenic to animals or
humans; and v) well produced in bacteria and yeasts at lowmanufactur-
ing costs [31]. Nanobodies have been successfully used for speciﬁc
targeting in different therapeutic approaches which comprise direct
blocking of receptors or viruses [32,33], chimeric fusion proteins
[34–36], and conjugation to drug carriers [31,37–39]. Nanobodies have
proven to be efﬁcient for the treatment of infectious protozoan diseases,
such as African trypanosomiasis [34] and malaria [40].
In the current study, we have taken advantage of the highly active
endocytosis process to speciﬁcally and effectively deliver drugs into
this protozoan parasite. The aim of this work was to develop a new
polyvalent drug delivery system for the treatment of African trypanoso-
miasis based on PLGA NPs conjugated with a nanobody that speciﬁcally
recognizes conserved cryptic epitopes on the parasite surface.2. Materials and methods
2.1. Chemicals
Water used in the experiments was deionized and ﬁltered with a
Milli-Q Academic System (Millipore, Saint Quentin-en-Yvelines,
192 J.L. Arias et al. / Journal of Controlled Release 197 (2015) 190–198France). All chemicals used were of analytical quality from Panreac
(Barcelona, Spain), except for PLGA 50:50 [molecular weight (Mw):
12000 Da; inherent viscosity: 0.24 dL/g], dextran-70, polyvinyl alco-
hol (PVA), NH2-PEG-COOH (Mw: 3 kDa), 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide (EDC), and N-hydroxysuccinimide (NHS) from
Sigma-Aldrich (Munich, Germany).
2.2. Nanobody puriﬁcation
The NbAn33 was expressed and puriﬁed as described previously
[41]. Brieﬂy, NbAn33 incorporating the pelB export signal and a six-
histidine-tag was expressed under the Lac promoter in Escherichia coli
WK6 cells (European Collection of Cell Culture). The nanobody was
puriﬁed from periplasmic extracts as described earlier [42]. The
six-histidine-tagged NbAn33 was puriﬁed using a Ni-NTA column
(Qiagen, Hilden, Germany), followed by gel ﬁltration on a Superdex
column (Amersham Biosciences, Uppsala, Sweden).
2.3. Synthesis of pentamidine-loaded NbAn33-coated PEGylated PLGA NPs
(NbAn33-pentamidine-PLGA NPs)
PLGA NPs were synthesized by a water-in-oil-in-water (w/o/w)
double emulsion/solvent evaporation (DE/SEV) methodology [43–45].
Brieﬂy, 3 mL of an aqueous solution of dextran-70 (1%, w/v) was added
to 10mL of a PLGA solution in ethyl acetate (2.5%,w/v), undermechanical
stirring (20,000 rpm). The resulting w/o emulsion was poured under
mechanical stirring (20,000 rpm) into 50mL of a 0.3% (w/v) PVA aqueous
solution. Stirringwas continued for 15min. As a result, a w/o/w emulsion
was formed, which was then diluted in 100 mL of a 2% (w/v) PVA
aqueous solution. Finally, mechanical stirring (1000 rpm, 25 °C) was
continued during 12 h to completely evaporate the organic solvent.
The colloidal suspension was then subjected to a cleaning procedure
that included repeated cycles of centrifugation (30 min at 11,000 rpm,
Centrikon T-124 high-speed centrifuge, Kontron, Zürich, Switzerland)
and re-dispersion in water, until the conductivity of the supernatant
was ≤10 μS/cm.
Standard EDC/NHS chemistry was used to link the heterofunctional
PEG chains (3 kDa, NH2-PEG-COOH) and the activated carboxyl groups
of the PLGA surface [19]. Carboxyl groups were activated in 5 mL of
isotonic 0.1 M 2-(N-morpholino) ethanesulphonic acid saline
(MES) buffer (pH 5.5) for 1 h at room temperature with EDC and
NHS (2:1.2 weight ratio). The “activated” PLGA NPs dispersion was
then centrifuged (11,000 rpm, 30 min) and re-suspended in 3 mL
of phosphate buffered saline (PBS, pH 7.4). The reaction of PLGA NPs
with HCl·NH2-PEG-COOH (1.3:1 weight ratio) was accomplished at
room temperature for 12 h. The resulting PEGylated (PEG-b-PLGA)
NPs were then centrifuged (11,000 rpm, 30 min) and washed with
PBS (pH 7.4) to remove the unbound PEG.
The nanobody was coupled to the PEGylated PLGA NPs (PLGA NPs)
via the EDC/NHS chemistry. Brieﬂy, a nanobody aqueous solution
(1 mg/mL) was added to the NP suspension (10:1 weight ratio) and
the system was allowed to react during 3 h under mechanical stirring
(200 rpm, room temperature). After that, 10 mL of PBS (pH 7.4) were
added, and the NP dispersion was centrifuged (11,000 rpm, 30 min). Fi-
nally, ﬂuorescent NPs to be used in the cell uptake experimentswere syn-
thesized using 5(6)-amino ﬂuorescein (1:10 equivalent ratio ﬂuorescein:
carboxyl groups) following the same chemistry.
The entrapment procedure for pentamidine loading was analogous
to that described for the preparation of the drug-unloaded NPs except
that the aqueous solution of dextran-70 further contained increasing
concentrations of pentamidine (up to 0.01 M). As a result, pentamidine-
loaded PEGylated PLGA NPs (pentamidine-PLGA NPs), and NbAn33-
pentamidine-PLGA NPs were obtained. The production performance
(yield, %) of all the formulation conditionswas also determined [(amount
of NPs obtained (mg)/sum of materials used in the preparation of the
NPs (mg)) × 100].2.4. Characterization methods
Photon correlation spectroscopy (PCS, Malvern Autosizer® 4700,
Malvern Instruments S.A., Worcestershire, UK) was used to determine
in triplicate the mean particle size (± standard deviation) of all the
polymeric particles at 25 °C. To that aim, the scattering angle was set
at 60°, and the measurement was done after an appropriate dilution of
the aqueous nanoparticulate dispersions (0.1%, w/v). In addition, the
stability of the nanoformulations was evaluated by measuring the size
of the particles after 1 month of storage in water at 4 °C.
PEGylation efﬁciency of the PLGA NPs was qualitatively determined
by 1H nuclear magnetic resonance (1H-NMR, Bruker AM-300, Bruker
Corporation, Billerica, USA). 1H-NMRdatawas obtained using deuterated
dimethyl sulfoxide (d6-DMSO) as solvent, and themost signiﬁcant bands
of PEG and PLGAwere identiﬁed. Chemical shifts weremeasured in parts
per million (ppm) using tetramethylsilane (TMS) as an internal
reference. In addition, the grafting density of PEG over the poly(D,
L-lactide) (PLA) backbone of the copolymer was calculated integrating
the peak of PEG (3.5 ppm) and PLGA (4.8 ppm) in the 1H-NMR
spectra.
Drug concentration in all the nanoparticulate formulations was
measured by ultraviolet–visible (UV–Vis) absorption measurements
(at the maximum absorbance wavelength: 261 nm, 8500 UV–Vis
Dinko spectrophotometer, Dinko Instruments, Barcelona, Spain),
using quartz cells of 1 cm path length. The spectrophotometric method
employed was previously validated by ultra-high-performance liquid
chromatography-tandemmass spectrometry (UPLC-MS/MS) and veriﬁed
for accuracy, precision, and linearity. Drug loading measurements were
done in triplicate by UV–Vis spectrophotometric quantiﬁcation of
the pentamidine remaining in the supernatant after NP centrifugation
(11,000 rpm, 30 min, 25 °C). Drug incorporation was expressed in
terms of pentamidine entrapment efﬁciency (%) [(mass of drug
incorporated (mg)/total mass of drug used in the loading experiments
(mg)) × 100], and pentamidine loading (%) [(mass of drug incorporated
(mg)/mass of NPs obtained (mg)) × 100].
Similarly, it was investigated the density of NbAn33 on the surface
of PLGA NPs. The procedure consisted in UV–Vis spectrophotometric
measurements of the nanobody remaining in the supernatant after NP
centrifugation (11,000 rpm, 30min, 25 °C). The method was previously
validated by UPLC-MS/MS.
The electrokinetic characterization of blank (drug unloaded) NPs and
drug-loaded NPs was used to conﬁrm the type of pentamidine loading
(surface adsorption, or absorption into the NPs). Zeta potential (ζ)
determinations (Malvern Zetasizer 2000 electrophoresis device,
Malvern Instruments S.A., Worcestershire, UK) were performed at 25 °C,
after 24 h of contact of the particles in water (≈0.1% w/v, at pH 5 and
1 mM KNO3, and under mechanical stirring: 50 rpm).
Pentamidine release experiments were performed in triplicate
following the dialysis bag method using the NbAn33-pentaamidine-
PLGA NPs with the greater drug entrapment efﬁciency values (≈72%,
see Table 1). To that aim, the dialysis bags were soaked in water for
12 h before use. Bags with a cut-off of 2000 Da (Spectra/Por® 6 dialysis
membrane tubing, Spectrum® Laboratories, New Jersey, USA) retained
the NPs and allowed the free pentamidine molecules to diffuse into the
release media. The release media was PBS at pH 7.4 or pH 5.0 at 37 °C.
Samples of 1 mL of NP dispersion (0.55 mg/mL of drug) were poured
into the bag with the two ends ﬁxed by clamps. Then, the bag was
placed in a conical ﬂask ﬁlledwith 150mLof PBS, andwasmechanically
stirred at 200 rpm. 1 mL samples of the medium were withdrawn at
different time intervals (0.5, 1, 3, 6, 9, 12, and 24 h, and 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, and 12 days) for UV–Vis spectrophotometric analysis
(261 nm). An equal volume of release medium, maintained at the
same temperature, was added after sampling to ensure sink conditions.
Furthermore, pentamidine release experiments were done under the
same experimental conditions used to coat pentamidine-PLGA NPs
with the nanobody (3 h, 25 °C, and mechanical stirring: 200 rpm). In
Table 1
Effect of pentamidine concentration on PLGANPs size, drug entrapment efﬁciency (%), drug loading (%), production performance (yield, %), and zeta potential values, (ζ (mV) at pH 5 and
1 mM KNO3).
[Pentamidine] (M) Size (nm) Pentamidine entrapment efﬁciency (%) Pentamidine loading (%) Production performance (%) ζ (mV)
0 142 ± 21 – – 97 ± 1 −23 ± 4
5 × 10−5 131 ± 29 27 ± 4 0.00552 ± 0.00082 95 ± 2 −25 ± 3
10−4 140 ± 22 41 ± 3 0.01675 ± 0.00122 96 ± 3 −22 ± 3
5 × 10−4 146 ± 32 52 ± 4 0.10622 ± 0.00817 97 ± 2 −23 ± 3
10−3 150 ± 28 59 ± 3 0.24102 ± 0.01225 95 ± 1 −25 ± 4
5 × 10−3 138 ± 27 64 ± 4 1.30721 ± 0.08171 96 ± 2 −24 ± 4
10−2 145 ± 35 72 ± 6 2.94123 ± 0.24511 97 ± 1 −22 ± 3
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during the NbAn33 coating procedure.
2.5. Trypanosomes and growth conditions
Monomorphic bloodstream T. brucei, strain AnTat 1.1 (Institute of
TropicalMedicine, Antwerpen, Belgium)was cultivated in hydrargyrum
medium-arc iodide-9 (HMI-9) medium supplemented with 20% heat-
inactivated foetal bovine serum (Sigma-Aldrich, Munich, Germany), at
37 °C in an atmosphere of 5% CO2.
2.6. In vitro viability assay
Cell viability was evaluated as previously described [46]. Eleven
dilution points were tested, ranging from 680 μM to 165 pM in
pentamidine concentration. The plates were read on an Inﬁnite® F200
PRO multimode reader (Tecan Group Ltd., Männedorf, Switzerland)
using an excitation wavelength of 535 nm and an emission wavelength
of 590nm.Data are the average of six determinations per concentration,
repeated thrice. The half-inhibitory concentration (IC50) value was
calculated (GraphPad Prism 5 software, GraphPad Software, Inc., La
Jolla, USA) as the drug concentration required to reduce the ﬂuorescence
output of the controls by 50%.
2.7. In vivo therapy experiment
Five C57BL/6J female mice (8-week-old, Jackson Laboratories, Bar
Harbor, USA) per group, and monomorphic AnTat 1.1 T. brucei were
used in this study. Mouse infection was obtained by intraperitoneal
(i.p.) injection of PBS (100 μL) containing 104 parasites. The number of
parasites in blood was estimated using a Neubauer counting chamber
(Laboroptik Co., Bad Hamburg, Germany) and a light microscope
(Leica Microsystems GmbH, Wetzlar Germany). The treatment was
administrated i.p. on days 3 (when the parasitemia was detectable), 7,
11, and 15 post infection, in a daily dose (volume: 200 μL/dose).
Pentamidine doseswere 0.025, 0.25, or 2.5mgkg−1 of free pentamidine
or pentamidine loaded into the NPs. The control group was treated
with saline serum (NaCl 0.9%). Animals were humanely sacriﬁced
when exhibiting severe disease symptoms, or if the parasitemia was
≥108 parasites/mL.
2.8. Field emission high resolution scanning electron microscopy
T. brucei bloodstream forms (107) were incubated (10min, 37 °C) in
1 mL of trypanosome dilution buffer (TDB) (5 mM KCl, 80 mM NaCl,
1 mM MgSO4, 20 mM Na2HPO4, 2 mM NaH2PO4, 20 mM glucose,
pH 7.4) containing 10 μg of NbAn33-PLGA NPs. Samples were washed
and resuspended in 0.5 mL of cold PBS. Parasites were ﬁxed (24 h,
4 °C) in 2.5% glutaraldehyde in a 0.1 M sodium cacodylate buffer
(pH 7.2) inside a humid chamber, and then mounted onto poly-L-
lysine slides (24 h, 4 °C). Sample post ﬁxation was performed in 2%
osmium tetroxide (1 h, room temperature). Then, samples were
dehydrated by incubating in 50%, 70%, 90%, and 100% ethanol
concentrations (two changes of 15 min in each) at room temperature.Critical point drying was performed in a Leica EM CPD300 critical
point dryer (Leica Microsystems GmbH, Wetzlar Germany). Samples
weremounted on stubs forﬁeld emission scanning electronmicroscopy
(FeSEM) and metalized in the presence of carbon in a Leica EM
CED030 carbon thread evaporator (Leica Microsystems GmbH,
Wetzlar Germany). Parasites were observed in an AURIGA dual beam-
focused ion beam (FIB)–FeSEM workstation (Carl Zeiss Microscopy
GmbH, Jena, Germany).
2.9. Nanoparticle uptake
Monomorphic bloodstream forms of T. brucei were incubated
(10 min, 37 °C) in TDB with ﬂuorescein-labelled NbAn33-PLGA NPs.
NP excess was removed by centrifugation. Then, the parasites were
re-suspended in TDB containing the tomato lectin-Alexa Fluor® 594
conjugate (a speciﬁc marker of the endocytic pathway in T. brucei [47]),
and incubation ended after 10 min (37 ° C) before ﬁxation. Finally, the
cells were ﬁxed in 4% paraformaldehyde (PFA) in PBS, and they
were then observed with a confocal laser-scanning microscope LSM
710 (Carl Zeiss Microscopy GmbH, Jena, Germany). Analysis of the
images was done with a ZEN 2012 imaging software (Carl Zeiss
Microscopy GmbH, Jena, Germany).
2.10. Ethics statement
The experiments, maintenance and care of mice complied with the
guidelines of the European Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientiﬁc Purposes (CETS
n° 123). In vivo experiments were approved by the Ethical Committee
for Animal Experiments of the Institute of Parasitology and Biomedicine
“López-Neyra” (CSIC, Granada, Spain).
3. Results
3.1. NP design and stability
The drug carrier was designed for active targeting of the trypanocidal
drug pentamidine to the T. brucei surface, as indicated in Fig. 1. PLGA
NPs were synthesized by a water-in-oil-in-water (w/o/w) double
emulsion/solvent evaporation (DE/SEV) technique [43–45], which
allowed the formation of well-stabilized particles with spherical
morphology and a narrow colloidal size distribution suitable for
parenteral administration (average diameter, 145 nm, Table 1). Particle
size is a critical parameter for the treatment of trypanosomiasis. NPs
should have an appropriate size to access the ﬂagellar pocket, the
unique location for endocytosis, through a narrow aperture between
the ﬂagellum and themembrane invagination [48]. Finally, PEG coating
density of PLGA NPs was 18% (mg of PEG at the surface for 100 mg of
particles).
To speciﬁcally target trypanosomes pentamidine-PLGA NPs were
coupled to nanobody NbAn33, which speciﬁcally recognizes a
conserved N-linked Man 5–9 (oligomannose) carbohydrate epitope
that is present in the GPI anchor of the parasite surface protein
(Fig. 1A) [41]. UV–Vis spectrophotometric measurements were
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amount of NbAn33 conjugated to the NPs was 0.08 mg of nanobody
per mg of NPs. Heterofuntional PEG3 KDa, NH2-PEG-COOH, chains
was employed to link NbAn33 to PLGA NPs (Fig. 1B). The molecular
weight of the PEG, 3 kDa, was an important parameter in the design
of this nanocarrier. Its chain length should be long enough to allow
the nanobody to reach its recognition epitope concealed within the
densely packed VSG surface coat (Fig. 1). Finally, particle size
and the quality of the nanoparticulate suspensions did not change
signiﬁcantly when the particles were loaded with different quantities
of the trypanocidal drug (Table 1). Both, the small size and PEG coating
prolong the circulation time of the NPs, thus enhancing their parasite
targeting capacity in the infected host [49,50].3.2. Pentamidine absorption into NbAn33-PLGA NPs
Table 1 shows the amount of trypanocidal drug absorbed by the NPs
as a function of the pentamidine concentration. It can be observed how
the drug concentration positively inﬂuenced the absorption efﬁciency
into the NPs. For instance, pentamidine entrapment efﬁciency (%) and
pentamidine loading (%) values rise from 12% and 0.0005% (when
the drug concentration was 10−5 M) to 72% and 3% (when the drug
concentration was 10−2 M), respectively. Remarkably, the production
performance (%) in all the formulations conditions was always ≥93%.
Thus, in vitro and in vivo studies were performed using the Nps with
the greater pentamidine entrapment efﬁciencies, i.e., 72% (Table 1).
The electrokinetic characterization of the NPs highlighted the
similarity between the zeta potential, ζ (mV) values of PLGA NPs
and pentamidine-PLGA NPs (Table 1). These results demonstrated
that pentamidine molecules were efﬁciently encapsulated into the
NPs rather than just adsorbed at the surface.3.3. Pentamidine release from NbAn33-pentamidine-PLGA NPs
Drug release from NbAn33-pentamidine-PLGA NPs was analyzed
at pH 7.4 (physiological pH) and pH 5 (lysosomal pH). Pentamidine
release was pH dependent and followed a biphasic proﬁle (Fig. 3),
characterized by an initial fast (burst) release (up to 45% in 12 h at
pH 7.4, and up to 35% in 1 h at pH 5) followed by a much slower
release phase (over a period of 11.5 days at pH 7.4, and over a period
of 23 h at pH 5). Such pentamidine release proﬁle conﬁrmed that the
major fraction of the drug was entrapped into the nanoparticle rather
adsorbed onto the particle surface. In addition, this release proﬁle
could be due to diffusion-cum-degradation mediated processes. The
ﬁrst phase may result from drug diffusion through the external side of
the nanoparticle [51–53]. The second pentamidine release phase could
be the consequence of drug diffusion through the nanoparticle structure,
nanoparticle degradation, or both [52–55].Fig. 3. Release of entrapped pentamidine from NbAn33-pentamidine-PLGA NPs as a functiFinally, it can be assumed that pentamidine loading into the PLGA
NPs was kept unaltered during surface functionalization with NbAn33,
given the negligible drug release (b3%) from the NPs.
3.4. In vitro cytotoxicity studies
The effectiveness of different pentamidine formulations was
evaluated in vitro using the resarzurin assay (Fig. 4). The half-
inhibitory concentration (IC50) of free pentamidine was 9.58 ±
0.27 nM (Fig. 4 A, B). Pentamidine loaded within PLGA NPs was
signiﬁcantly more efﬁcient at killing trypanosomes. As shown in
Fig. 4B, there was a 3-fold reduction in the IC50 of pentamidine-PLGA
NPs relative to free drug. Finally, the IC50 of NbAn33-pentamidine-
PLGA NPs was 1.37 ± 0.10 nM, which represented a 7-fold reduction
in the IC50 relative to free drug (Fig. 4B). Thus, active targeting with
the nanobody yielded an additional 4-fold reduction of the IC50 relative
to passive targeting, emphasizing the importance of the nanobody
coating in the effectiveness of the nanocarrier.
Several in vitro studies have described drug delivery systems based
on PLGA NPs for the passive targeting of protozoan parasite infections,
mainly Leishmaniasis, Malaria and Chagas disease [56–59]. In all cases,
only small decreases in IC50 relative to free drugs were obtained.
Therefore, our results highlight the importance of active targeting
to treat infectious protozoan diseases.
3.5. In vivo therapy studies
We next assayed the efﬁcacy of NbAn33-pentamidine-PLGA NPs
in vivo in an acute murine model of African trypanosomiasis. The
minimal full curative dose of free pentamidine is a daily intraperitoneally
dose of 2.5 mg kg−1 for four days [60,61]. Therapeutic treatments began
on the 3rd day post-infection and untreated animals died at day 5
(Fig. 5). Mice were also treated with free pentamidine and NbAn33-
pentamidine-PLGA NPs at 10- and 100-fold lower doses than the
minimal full curative dose, 0.25 and 0.025 mg kg−1, respectively
(Fig. 5).
NbAn33-pentamidine-PLGA NPs cured all infected mice at a 10-fold
lower dose (0.25mg kg−1). At the same dose, all mice treated with free
pentamidine died between days 24 and 27 post infection. At a 100-fold
lower dose, the NbAn33-pentamidine-PLGA NPs formulation cured 60%
of mice, while free pentamidine failed to cure any of the treated
mice, killing all animals between days 5 and 19 after infection.
Pentamidine-PLGA NPs (without nanobody coating) at a 10-fold
dilution (0.25 mg kg−1) cured 40% of treated mice, while at a 100-fold
dilution (0.025 mg kg−1) all mice died between days 18 and 23
postinfection.
According to these results, our system seems to be more effective
in vivo than in vitro, with at least a 10-fold reduction of the full curative
dose relative to free drug. These results clearly demonstrate the decisiveon of the incubation time in PBS pH 7.4 (right panel) and pH 5.5 (left panel) at 37 °C.
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delivery system.
3.6. NbAn33-pentamidine-PLGA NPs bind to trypanosome surface and are
endocytosed
The binding capacity of NbAn33-pentamidine-PLGA NPs to the
parasite surfacewas assessed by FESEM(Fig. 6). Spherical NPs of different
sizeswere clearly observed adhered to the trypanosome surface (Fig. 6b).
Asmentioned above, NPs size is a critical parameter as they have to cross
a small aperture to access the ﬂagellar pocket (Fig. 6c).
Finally, to visualise drug entrance and localisation NbAn33-PLGA
NPs labelled with ﬂuorescein were incubated with live trypanosome
in the presence of Alexa 594-tomato lectin, a speciﬁc marker of the
endocytic pathway in T. brucei [47]. As expected, labelled NbAn33-
PLGANPswere detected on the surface of the parasite being internalized
and accumulating in the endocytic pathway (Fig. 7). Pentamidine needs
to reachhigh intracellular concentrations for effective activity [62]. Thus,
the nanocarrier concentrates NPs drug cargo via the endocytosis path-
way into the cytoplasm, increasing the efﬁcacy of the drug.
4. Discussion
This investigation is devoted to the development of a new drug
delivery system for the active targeting of pentamidine toward African
trypanosomes. Concretely, the nanoplatform is based on PLGA NPs
functionalized to obtain passive drug targeting capabilities (PEGylation
for extended plasma circulation times) and active drug targeting capa-
bilities (surface decoration with NbAn33 moieties that can speciﬁcallyFig. 5. In vivo therapy experiments. Survival (Kaplan-Meier plot) of female C57BL/6J mrecognize cryptic epitopes onto the surface of T. brucei). NP synthesis
was based on a reproducible w/o/w DE/SEV methodology, and NP
functionalization with PEG chains and nanobody moieties relied on a
standard EDC/NHS chemistry.
Under the best formulation conditions, well-stabilized spherical NPs
were obtained, suitable for the parenteral route of administration
(average diameter ≈ 145 nm, Table 1). Both, the small size and PEG
coating may contribute to the extended blood circulation times, thus
facilitating the active drug targeting to the parasite [49,50]. Even
more, such properties are specially relevant, given the fact that the
NPs should have an appropriate size to access the ﬂagellar pocket,
the unique locationwhere endocytosis occurs at the narrow aperture
between the ﬂagellum and the membrane invagination [48]. In addi-
tion, the length of the PEG chains (Mw: 3 kDa) was enough to allow
the nanobody to reach the recognition epitope located within the
densely packed VSG (Fig. 1A).
Pentamidine loading procedure yielded signiﬁcant drug entrapment
efﬁciencies and sustained drug release properties (Table 1, Fig. 3). In
addition, NP composition determined a pH-responsive drug release
which could be the consequence of the speciﬁc polymer breakage in
acidic environments (those existing within the lysosomes of the
parasite). Such drug release behaviour can be considered advantageous
for intracellular pentamidine delivery.
Regarding the preclinical tests, pentamidine activity in vitro
against trypanosomes was signiﬁcantly optimized when the drug
was incorporated within the nanoparticulate formulation. Concretely,
7-fold reduction was obtained in the IC50 values relative to the free
drug, and also an additional 4-fold reduction in the IC50 levels relative
to the PEGylated nanoformulation (Fig. 4), this emphasizing the criticalice infected with T. brucei AnTat1.1 (104 parasites). Vehicle; physiological serum.
Fig. 6. Field emission scanning electronmicrographs. (A) Bloodstream forms of T. bruceiAnTat1.1 strain coated byNbAn33-PLGANPs. (B) Detail of the parasite surface showing boundNPs.
(C) A view of the ﬂagellar pocket aperture with NPs in the process of being endocytosed. FP, ﬂagellar pocket aperture; F, ﬂagellum.
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effective activity of pentamidine when loaded to the nanoparticulate
system surface functionalized with NbAn33 molecules was conﬁrmed
in vivo (Fig. 5): it was determined at least a 10-fold reduction in theFig. 7. NbAn33-pentamidine-PLGA NPs internalized and accumulated in the endocytic
pathway. A) Live monomorphic bloodstream forms of T. brucei AnTat1.1 were incubated
with ﬂuorescein labelled NbAn33-PLGA NPs (green) for 10 min at 37 °C. NP excess was
removed and the parasites were incubated with tomato lectin-Alexa Fluor 594 conjugate.
Samples were taken after 1 min (A) and 10 min (B) of incubation. Nuclei and kinetoplasts
(mitochondrial DNA) were stained with DAPI, in blue. N, nuclei. K, kinetoplast.minimum full curative dose relative to the free drug. Such optimized
cytotoxic activity may contribute to the reduction of the pentamidine
doses needed to assure a therapeutic effect and, subsequently, to the
minimization of the adverse side effects associated to the mechanism
of action of the drug.
Finally, an additional proof-of-concept was done to investigate the
binding capacity of NbAn33-PLGA NPs to the parasite surface. FeSEM
observations demonstrated the interaction of the NPs with the ﬂagellar
pocket (Fig. 6), a key step prior to particle uptake by endocytosis [48].
In addition, confocal microscopy analysis conﬁrmed the particle
uptake/internalization by endocytosis (Fig. 7). Thus, the drug (loaded to
the NPs) may satisfactorily enter into the cytoplasm of the trypanosome
via the endocytic pathway, leading to the highly enough intracellular
drug concentrations that will display the efﬁcient cytotoxic activity [62].5. Conclusions
This study demonstrates that the trypanosome surface is an excellent
therapeutic target due to the high turnover of the entire cell membrane.
The small size of nanobodies allows them to reach conserved epitopes
located in locations which are inaccessible to conventional antibodies.
Nanobody conjugation was essential for the effectiveness of the
formulations in both in vitro and in vivo experiments. Our system
employs components approved for their use in humans, including
nanobodies, and may be loaded with drugs that are currently in use
for HAT, making them ready for their practical use in therapy. Thus,
this effective and ﬂexible targeted drug delivery system represents
197J.L. Arias et al. / Journal of Controlled Release 197 (2015) 190–198an alternative therapeutic approach to the actual anti-trypanosome
therapies and it could be easily adapted to treat other diseases.
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